Precision Biosciences (DTIL) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The PBGENE-DMD Phase 1/2a (FUNCTION-DMD) study is an early-stage trial run by Precision BioSciences, Inc. to test a new genetic treatment for Duchenne muscular dystrophy. It aims to assess safety, side effects, and early signs of benefit in boys whose disease is linked to a specific set of gene errors, a sizable subgroup with limited current options.
The treatment, called PBGENE-DMD, is a one-time intravenous genetic therapy designed to cut out faulty exons 45-55 in the dystrophin gene. The goal is to restore production of a more functional form of the muscle protein and offer a long-lasting effect from a single dose.
The study is interventional and uses a single group design, meaning all enrolled patients receive PBGENE-DMD rather than being split into treatment and control arms. It is open label, so both doctors and families know the treatment being given, and the main purpose is to treat and track safety and early benefit over time.
The trial will enroll up to 18 participants in two stages, starting with a small safety group and then expanding if the data look acceptable. Each participant will be followed for around 130 weeks after dosing, giving a long window to spot both short-term issues and early signs of durability.
The study was first submitted on February 17, 2026, signaling the move from preclinical work into human testing. The most recent update was filed on March 12, 2026, and the study is listed as not yet recruiting, so investor focus should be on upcoming site activation and first-dose milestones.
From a market angle, this update confirms Precision BioSciences is executing on its in vivo gene editing strategy in a high-need area, which can support sentiment around DTIL as a platform story. Early human data, once available, will be the key catalyst, and investors will likely compare progress and safety to other Duchenne gene therapies from larger players such as Sarepta and Pfizer.
If PBGENE-DMD shows a clean safety profile and even modest functional gains, it could boost confidence in Precision’s pipeline and raise the perceived value of its gene editing approach. On the flip side, any safety concerns may weigh on the stock and impact how investors view the broader gene editing space, which is already under close regulatory and market scrutiny.
This PBGENE-DMD trial for Duchenne muscular dystrophy is currently listed as not yet recruiting but recently updated, and further details are available on the ClinicalTrials portal.
To learn more about DTIL’s potential, visit the Precision Biosciences drug pipeline page.